Phathom Pharmaceuticals, Inc.
PHAT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001783183
No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.
Holders of 5% or more of PHAT
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Phathom Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P. | 13D/A | 7.40%6.01M shares | −1.20 ppfrom 8.60% | May 5, 20238 filings | Nov 2, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.50%4.38M shares | +0.90 ppfrom 4.60% | Oct 21, 20244 filings | Jul 29, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
57 Schedule 13D and 13G filings on Phathom Pharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 20265:04 PM ET | Invesco Ltd. | 13G/A | 0.00%30.6K shares | –Below 5% | Sep 30, 2026 | SEC |
| Nov 2, 20264:20 PM ET | Frazier Life Sciences Public Fund, L.P.and 16 others | 13D/A | 7.40%6.01M shares | −1.20 ppfrom 8.60% | Oct 29, 2026 | SEC |
| Jul 29, 20263:19 PM ET | BlackRock, Inc. | 13G | 5.50%4.38M shares | +0.90 ppfrom 4.60% | Jun 30, 2026 | SEC |
| Jul 20, 20265:52 PM ET | Millennium Management LLCand 2 others | 13G/A | 4.20%3.38M shares | −1.10 ppfrom 5.30%Below 5% | Jun 30, 2026 | SEC |
| Mar 12, 20264:46 PM ET | Millennium Management LLCand 2 others | 13G | 5.30%4.18M shares | +2.60 ppfrom 2.70% | Mar 6, 2026 | SEC |
| Jan 27, 20264:25 PM ET | Millennium Management LLCand 3 others | 13G/A | 2.70%2.08M shares | −4.40 ppfrom 7.10%Below 5% | Dec 31, 2025 | SEC |
| Nov 4, 20255:24 PM ET | Frazier Life Sciences Public Fund, L.P.and 16 others | 13D/A | 8.60%5.99M shares | 0.00 ppfrom 8.60% | Nov 1, 2025 | SEC |
| Nov 3, 20254:22 PM ET | Millennium Management LLCand 3 others | 13G/A | 7.10%5.08M shares | +1.20 ppfrom 5.90% | Sep 30, 2025 | SEC |
| Aug 28, 20254:30 PM ET | Carlyle Group Inc.and 10 others | 13G/A | 4.90%3.50M shares | –Below 5% | Aug 28, 2025 | SEC |
| Aug 25, 20254:12 PM ET | Millennium Management LLCand 3 others | 13G/A | 5.90%4.16M shares | +0.60 ppfrom 5.30% | Aug 19, 2025 | SEC |
| Aug 20, 20255:18 PM ET | Frazier Life Sciences Public Fund, L.P.and 22 others | 13D/A | 8.60%5.99M shares | −11.30 ppfrom 19.90% | Aug 18, 2025 | SEC |
| Aug 13, 20254:00 PM ET | Millennium Management LLCand 2 others | 13G | 5.30%3.76M shares | New | Aug 11, 2025 | SEC |
| Jun 9, 202510:47 AM ET | Jennison Associates LLC | 13G/A | 0.00%0 shares | 0.00 ppfrom 0.00%Below 5% | May 31, 2025 | SEC |
| Jun 6, 20251:29 PM ET | Prudential Financial Inc | 13G/A | 0.00%2.63K shares | −11.00 ppfrom 11.00%Below 5% | May 31, 2025 | SEC |
| Jun 4, 20254:30 PM ET | Jennison Associates LLC | 13G/A | 0.00%0 shares | –Below 5% | Apr 30, 2025 | SEC |
| May 13, 20254:22 PM ET | Frazier Life Sciences Public Fund, L.P.and 22 others | 13D/A | 19.90%14.4M shares | – | May 9, 2025 | SEC |
| Apr 24, 20252:30 PM ET | BlackRock, Inc. | 13G/A | 4.60%3.23M shares | –Below 5% | Mar 31, 2025 | SEC |
| Nov 12, 2024 | BlackRock, Inc. | 13GOld format | – | – | – | SEC |
| Nov 5, 20244:12 PM ET | Prudential Financial Inc | 13G/A | 11.00%7.42M shares | +1.70 ppfrom 9.30% | Oct 31, 2024 | SEC |
| Nov 5, 20243:32 PM ET | Prudential Financial Inc | 13G | 9.30%6.28M shares | New | Sep 30, 2024 | SEC |
| Nov 4, 2024 | Jennison Associates LLC | 13GOld format | – | New | – | SEC |
| Oct 21, 2024 | BlackRock, Inc. | 13GOld format | – | New | – | SEC |
| Aug 22, 2024 | Frazier Life Sciences Public Fund, L.P. | 13D/AOld format | – | – | – | SEC |
| Jun 6, 2024 | Frazier Life Sciences Public Fund, L.P. | 13D/AOld format | – | – | – | SEC |
| Apr 10, 2024 | Takeda Pharmaceutical Co Ltd | 13D/AOld format | – | – | – | SEC |
| Apr 1, 2024 | Takeda Pharmaceutical Co Ltd | 13D/AOld format | – | – | – | SEC |
| Feb 12, 2024 | Carlyle Group Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2024 | Invesco Ltd. | 13G/AOld format | – | – | – | SEC |
| Jan 26, 2024 | Medicxi Growth I LP | 13G/AOld format | – | – | – | SEC |
| Jan 25, 2024 | Takeda Pharmaceutical Co Ltd | 13D/AOld format | – | – | – | SEC |
| May 26, 2023 | Frazier Life Sciences Public Fund, L.P. | 13D/AOld format | – | – | – | SEC |
| May 5, 2023 | Frazier Life Sciences Public Fund, L.P. | 13D/AOld format | – | – | – | SEC |
| Mar 9, 2023 | Carlyle Group Inc. | 13GOld format | – | New | – | SEC |
| Feb 14, 2023 | Avidity Partners Management LP | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2023 | Flynn James E | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2023 | Janus Henderson Group PLC | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2023 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Feb 2, 2023 | Invesco Ltd. | 13G/AOld format | – | – | – | SEC |
| Jan 31, 2023 | Medicxi Growth I LP | 13G/AOld format | – | – | – | SEC |
| Sep 26, 2022 | Frazier Life Sciences IX, L.P. | 13D/AOld format | – | – | – | SEC |
| Sep 23, 2022 | Flynn James E | 13GOld format | – | New | – | SEC |
| Aug 11, 2022 | Frazier Life Sciences IX, L.P. | 13D/AOld format | – | – | – | SEC |
| May 16, 2022 | Ra Capital Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Ra Capital Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Avidity Partners Management LP | 13GOld format | – | New | – | SEC |
| Feb 10, 2022 | Janus Henderson Group PLC | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2022 | Yamada Tadataka | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2022 | Vanguard Group Inc | 13GOld format | – | New | – | SEC |
| Feb 10, 2022 | Invesco Ltd. | 13G/AOld format | – | – | – | SEC |
| Nov 12, 2021 | Takeda Pharmaceutical Co Ltd | 13D/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Phathom Pharmaceuticals, Inc. shares.
No Form 144 notices for Phathom Pharmaceuticals, Inc. are on file.